Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of solid organ transplantation. The current report presents the case of a 42-year-old male who developed PTLD within the first year following renal transplantation. The disorder manifested as a tumor adjacent to the lower pole of the renal allograft and resulted in urinary obstruction. Durable complete remission was achieved as a result of surgical resection followed by a reduction in immunosuppression and low-dose rituximab-based chemotherapy, indicating that this therapeutic strategy may be safe and effective for the treatment of specific cases of localized and resectable PTLD.
Highlights
Post‐transplant lymphoproliferative disorder (PTLD) is a rare, but critical complication that occurs following solid organ and hematopoietic stem cell transplantation [1]
The current study describes a rare case of PTLD that presented as Correspondence to: Dr Longkai Peng, Department of Urological Organ Transplantation, Second Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, Hunan 41011, P.R
During the 16‐month follow‐up after resection, the patient remained in remission, neither Epstein‐Barr virus (EBV) viremia nor PTLD recurred and renal allograft function was preserved
Summary
The donor and recipient were seronegative for cytomegalovirus, and the Hepatitis B and C viruses. Good renal allograft function was observed immediately following surgery. On the twelfth postoperative day, the patient exhibited a serum creatinine level of 133 μmol/l (normal range, 44‐133 μmol/l) and was discharged. The allograft function remained normal during the out‐patient follow‐up, seven months post‐transplantation, the patient developed a fever, oliguria and an elevated serum creatinine level (410.7 μmol/l). Serum creatinine returned to within the normal range following treatment of the urinary obstruction. The patient's blood was negative for EBV DNA following the first cycle of chemotherapy. During the 16‐month follow‐up after resection, the patient remained in remission, neither EBV viremia nor PTLD recurred and renal allograft function was preserved.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
